FDA (CDER)
GUIDANCE FINAL
M15 General Principles for Model-Informed Drug Development
Published: 6/2/2026Detected: 6/2/2026
Summary preview
Sets out general FDA principles for integrating model-informed approaches into drug development decisions across clinical, safety, quality, and labeling evidence packages.
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountclinical
safety
manufacturing
labeling
quality
#model-informed drug development
#MIDD
#dose selection
#exposure-response
#clinical trial design
Official Source Document Source Verified
Access the original document directly from FDA CDER.
More from FDA (CDER)
- E2B(R3) Electronic Transmission of Individual Case Safety Reports Implementation Guide — Data Elements and Message Specification; and Appendix to the Implementation Guide — Backwards and Forwards Compatibility10/1/2026
- Temporary Policies for Compounding Certain Starter Parenteral Nutrition Drug Products for Neonates: Guidance for Industry9/8/2026
- Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing and Labeling9/2/2026
- Evaluation of Therapeutic Equivalence8/21/2026
- Determining Whether to Submit an ANDA or a 505(b)(2) Application8/17/2026